Debt-to-equity in % of Rani Therapeutics Holdings, Inc. from Q2 2022 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Rani Therapeutics Holdings, Inc. quarterly Debt-to-equity history and change rate from Q2 2022 to Q3 2025.
  • Rani Therapeutics Holdings, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -764%, a 236% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Rani Therapeutics Holdings, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -764% -1,326% -236% 30 Sep 2025
Q2 2025 -3,593% -3,950% -1,106% 30 Jun 2025
Q1 2025 2,833% +2,603% +1,132% 31 Mar 2025
Q4 2024 965% +803% +495% 31 Dec 2024
Q3 2024 562% +434% +339% 30 Sep 2024
Q2 2024 357% +263% +280% 30 Jun 2024
Q1 2024 230% +169% +277% 31 Mar 2024
Q4 2023 162% +126% +343% 31 Dec 2023
Q3 2023 128% +110% +606% 30 Sep 2023
Q2 2023 94% +85% +930% 30 Jun 2023
Q1 2023 61% 31 Mar 2023
Q4 2022 37% 31 Dec 2022
Q3 2022 18% 30 Sep 2022
Q2 2022 9% 30 Jun 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.